logo-loader

CBD Science looks to raise £2M in Series A to advance its plant-based cannabinoid therapy in the UK

Published: 16:24 21 Sep 2021 BST

CBD Science Group PLC CEO Dr Michael Raymont joined Proactive New York to discuss the London, England-based group's Series A funding round, on the Crowd for Angels platform.

Raymont says the privately-held company, which is developing plant-based cannabinoid pharmaceutical therapeutics to treat cancer related pain will look to raise £2 million at £0.50 per share, where it will use the funding to assess data from its upcoming clinical trials and to shore up its supply chain so it can continue to produce and supply its material.

HANetf founder and co-CEO discusses shift to active management in ETF market

HANetf founder and co-CEO Hector McNeil tells Proactive's Stephen Gunnion about shifting trends in the exchange-traded fund (ETF) market in the United States, indicating a big move towards active management within ETFs. Despite the European market lagging behind the US by three to five years,...

13 hours, 11 minutes ago